Status:

ENROLLING_BY_INVITATION

Brain Stimulation and Sensory Integration in Children With ASD

Lead Sponsor:

Neurolab Plus

Collaborating Sponsors:

Al-Farabi Kazakh National University (KazNU)

Conditions:

Autism Spectrum Disorder (ASD)

Eligibility:

All Genders

6-12 years

Phase:

NA

Brief Summary

The goal of this clinical trial is to find out if brain stimulation can help improve sensory integration in children ages 6 to 12 with autism spectrum disorder (ASD). The main questions it aims to ans...

Detailed Description

This study explores how noninvasive brain stimulation may support children with Autism Spectrum Disorder (ASD) by improving how their brains process and combine sounds and images. It also investigates...

Eligibility Criteria

Inclusion

  • Children aged 6-12 years at the time of enrollment.
  • Clinical diagnosis of Autism Spectrum Disorder (ASD) confirmed using the Autism Diagnostic Interview-Revised (ADI-R).
  • Intelligence quotient (IQ) ≥ 70 as measured by the General Ability Index (GAI) from the Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V).
  • Ability to understand and follow simple instructions for behavioral tasks and stimulation procedures.
  • Stable medication regimen (if any) for at least 4 weeks before the start of the study.
  • Written informed consent from a parent or legal guardian, and assent from the child when appropriate.

Exclusion

  • History of epilepsy, seizures, or abnormal EEG suggestive of seizure risk.
  • Presence of metal implants, devices, or foreign bodies in or near the head (except dental fillings) that are contraindicated for TMS or MRI.
  • Serious neurological disorders other than ASD (e.g., cerebral palsy, brain injury, neurodegenerative disease).
  • Severe psychiatric disorders requiring hospitalization or urgent intervention.
  • Current or past history of significant head trauma with loss of consciousness \> 5 minutes.
  • Uncorrected hearing or vision problems that could interfere with task performance.
  • Inability to tolerate sitting still for 15-20 minutes.
  • Participation in another interventional clinical trial within the past 3 months.

Key Trial Info

Start Date :

August 25 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2026

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT07182331

Start Date

August 25 2025

End Date

June 1 2026

Last Update

September 19 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Neurolab Plus

Almaty, Kazakhstan, 050000

2

Non-profit joint-stock company "Al-Farabi Kazakh National University"

Almaty, Kazakhstan, 050040